ZELTIQ Aesthetics Inc was incorporated in the state of Delaware on March 22, 2005. In August 2011, the Company incorporated ZELTIQ Limited as a wholly-owned subsidiary in the United Kingdom to serve as its sales office for direct sales in Europe. The Company was founded to develop and commercialize a non-invasive product for the selective reduction of fat. On October 24, 2011, the Company completed its initial public offering, or IPO, of 8,050,000 shares of common stock, of which 7,743,000 shares were sold by the Company and 307,000 shares were sold by existing stockholders. The Company generates revenue from sales of CoolSculpting system and from sales of consumables to its customers. Its geographical region includes North America and International. The Company's first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. The Company manufactures and distributes its CoolSculpting system, including procedure packs, at its Dublin facility. The Livermore facility is used primarily for raw material storage. Through 2012 and the beginning of 2013, the Company has utilized OnCore Manufacturing LLC to manufacture and supply CoolSculpting system. ZELTIQ, CoolSculpting, and Company's logo are registered trademarks in the United States and in certain foreign countries. The design, development, manufacture, testing and sale of products are subject to regulation by governmental authorities, mainly FDA, and corresponding state and foreign regulatory agencies.